Sitemap - 2023 - The California Stem Cell Report
California Stem Cell Report Going Dark for Holidays
Cells, Genes and Sheersha: A Six-Year-Old California Girl and a Different Sort of Christmas Story
"CIRM 3.0" and Its New Interim President
Looking for Work? How About a Career in Law and Biosciences?
The California Stem Cell Report: Authoritative, Respected, Independent, Unique and 'Essential'
CIRM Names Interim President: Jonathan Thomas, Former Chair of the CIRM Governing Board for 11 Years
The CIRM CEO Search: Perils of an Interregnum and Handcuffs
The CIRM CEO Search: Creeping Ahead with Criteria and a Search Firm
The CIRM CEO Search: 'Big Fish, Small Tank?'
Bluebird Bio: 'How Did They Screw Up So Badly?' Company's Future in Limbo
The California Stem Cell Report: Authoritative, Respected, Independent, Unique and 'Essential'
With CIRM Millions, UC Davis stem cell ‘fairy godmother’ leads fight against spina bifida
Seeding the Field 10 Years Ago with $32 Million; A CIRM Story About a Biobank and Stem Cells
CIRM CEO Search: Staff Morale 'Crisis' at Agency, Board Member Predicts Possible 12-Month Search
CIRM CEO Search: Decision Delayed on Interim President; Search Committee Named
'Confidential' Science, Billions in Public Dollars and the Public's Trust or Lack of It
The CIRM CEO Search: The Agency Expresses Concern About an Item on This Newsletter
California Taxpayers Barred from Tomorrow's Key Meeting of the State's $12 Billion Stem Cell Agency
Happy Birthday to CIRM! The California Gene and Stem Cell Research Program is Turning 19.
Presidential Vacancy at California's Stem Cell Agency Triggers Hiring Pause
CEO of California Stem Cell Agency Quits Abruptly; No Interim Replacement Named by Governing Board
CEO of California's $12 Billion Stem Cell Agency Resigns
California Proposal to Lure Fledgling Stem Cell and Gene Therapy Companies
Another Live Blog on the FDA Sickle Cell Hearing; This One from BioPharma Dive
From UC Irvine: New Study of Dubious Stem Cell Clinics and Their Pitches for Their "Cures"
Tracking the CIRM: Strategy and the Golden State's Stem Cell and Gene Therapy Trail
Measuring the Financial Impact of California Stem Cell Spending: A Big Data Task
California Stem Cell Agency Pumped Nearly $1 Billion into Neuro Disease Research
Stem Cells, Genes, Neuro Diseases and Stingy Information Sharing
California's New, $111 Million Probe into Mental Illnesses, their Genetic Origins and Mechanisms
How Long Does the California Stem Cell Agency Have to Live?
Priorities for $4 Billion: California's Stem Cell/Gene Therapy Program Eyeing Changes
CIRM Openness, the Neuro Task Force and a Public Comment
An Ethical Dilemma, Cord Blood and Regenerative Medicine: The NY Times Digs into a Case in New York
Tracking the CIRM: $31 Million in Research Awards, $7 Million More for 'Scholars'
'Rocketing' Stock Price for Rare Disease Firm; Good News for California Stem Cell Agency
Reading Recommendations: From the New Yorker to a 'Quagmire'
Tracking the CIRM: How Does It Tell Its Story? A Question for Its Directors
Billions of Dollars, Deliverables and California Stem Cell Spending Strategies
California's Neuropsychiatric Disease Probe Could Hit $111 Million
'ReMind' -- California's Plan to Plug Gaps in Origins of Neuropsychiatric Disease Up for Action
CIRM's $1.5 Billion Neuro Task Force Still Looking for Ways to Spend the Cash
Stem Cell Hype and Slow Science: 'Not One' Treatment after 25 Years of Research
Perfect 10: CIRM Board Members' Rationale Behind the Superlative Scores
Rubric for Equality: How Does the California Agency Score DEI
New Clinical Trial to Transform Skin Cells into a Treatment for Parkinson's Disease
The Gene Therapy 'Quagmire:' Multimillion- Dollar Costs and Untreated Patients with Rare Diseases
Tracking the CIRM: Light Public Schedule During the Dog Days of Summer
California Stem Cell Clinical Trials Crack the 95 Mark and Include Blindness, HIV, ALS
$50 Million in Awards This Week by California's Stem Cell and Gene Therapy Agency
California Stem Cell Agency's Newest Board Member -- Kevin Xu
$90 Million Neuropsychiatric Research Plan Hits Bump at California's Stem Cell Agency
10x Less: A Proposal to Slash Multimillion-Dollar Costs of Gene Therapies by a Factor of 10
A Looming Political Reality for a $12 Billion Stem Cell and Gene Therapy Research Program
Breaktime for the California Stem Cell Report
California Scatters $1 Billion in Neuro Disease Research Over 13 Areas
High on Selling Hope, Less So on Production of Revolutionary Therapies
Upcoming: A Longer Look at the Nearly Half-Billion Dollar CIRM Research Budget and Its Implications
Tracking the CIRM: 89th Clinical Trial and a $21 Million Day
California to Spend Nearly Half-Billion on Gene Therapy and Stem Cell Research in Next Fiscal Year
Former CIRM Board Member Zeroes in on 'Irrational and Bizarre Schema' of Therapy Pricing
Tracking the CIRM: Spring Time is Money Time at the $12 Billion California Stem Cell Agency
Key Information Missing on California's Neuro Disease Program Scheduled for Action on Monday
Doudna Speaks Out on Multimillion-Dollar Pricetags for Revolutionary Cures
California's Bubble Baby Saga: CIRM Touts its Role in Maintaining the Once Abandoned Clinical Trial
Pressure Points and Affordability of Revolutionary Therapies: California Creeping Toward Solutions
CNN Portrays the Plight of the 'Bubble Babies,' An Effective Therapy but No Access
'Keeping the Fire Going' and the California Stem Cell Report
Delivering Revolutionary Cell/Gene Therapies to the Underserved, Creating More Accessibility
Tracking the CIRM: $52 Million Week, $1.5 Billion Neuro Program, $155 Million Affordability Session
California State Effort to Advance as 'World-Class Hub' in Stem Cell/Gene Therapy Manufacturing
Tracking the CIRM: Agency Mulls Financing for Neuropsychiatric Research
Quote of the Day: No Faint-Hearted Scientists Needed
Crossing the Financial Valley of Death: A Hurdle for Stem Cell and Gene Therapies
The Ballot Box, California Stem Cell Research and Dual Executives
Twelve Years Before the CIRM Mast: Jonathan Thomas Reflects on Accomplishments and the CIRM Team
Tracking the CIRM: Webinar This Week on Basic Research Grant Offerings.
State Stem Cell Agency Approves $26 Million to Remove Obstacles to Gene and Cell Therapy Treatments
Tracking the CIRM: New Chair for $12 Billion Program, $26 Million to Hurdle Research Obstacles
New, $2.5 Billion Fed Program to Improve Health Outcomes; Will it Have a California Outpost?
Silicon Valley Bankout Fallout: A Q&A With the California Cell and Gene Therapy Program
California's Approach to Financing Neuro Disease Research Taking a Turn to Mental Disorders
An Affinity Examined: The Biotech Community and a Failed California Bank
Affordability and Multimillion-Dollar Treatments: The 28-Month-Old Challenge in California
Ripple Effects? California's Stem Cell Agency and the Collapse of Silicon Valley Bank
Regenerative Medicine in the Golden State and Telling its Multibillion Dollar Story
$1.5 Billion Up For Grabs on Neuro Diseases: California is Devising Plan on How to Spend It
New General Counsel at California Stem Cell Agency is Rafael Aguirre-Sacasa
'The Next Chunk of Gold:' New CRISPR Fight Brewing
Tracking the CIRM: Learn How it Pursues High-Risk, High-Reward Research Next Month
A Genetic Case of Limited Resources: Sickle Cell Trial Cancelled, Layoffs at Graphic Bio
$100 Million in Clinical Funding by California's Stem Cell Agency During Last Eight Months
A Story About California's $1.5 Billion for Neuro Research: No Scientists Expressed an Interest
California to Beef Up Potential Treatment for Arthritic Knees with Nearly $12 Million
Nobel Prize Winner Paul Berg Dies at the Age of 96
Prelude to Thinking About $1.5 Billion: Fresh Info on California's Neuro Disease Portfolio
Strategy for $1.5 Billion: Creating a New Pathway for Financing Neuro Disease Research
The Money Trail at California's Stem Cell Program: How the Billions Are Rationed
Taxpayer Financing of Medical Research and Zero Responsibility to Consumers: 'We Have to End That'
Six Words and CIRM: A Blessing from The White House
California and the Multimillion-Dollar Costs of Gene Therapies that the State is Helping to Finance
Vito Imbasciani and the 'Nonpareil' California State Stem Cell Agency
Tracking The CIRM: Affordability, Community Centers Coming Up Next Tuesday
CIRM Directors Now in Executive Session Interviewing Board Candidates
Text of Emilie Marcus' Statement to the Governing Board of the California Stem Cell Agency
Text of Vito Imbasciani's Statement to the Governing Board of the California Stem Cell Agency
Riverside and a Cell/Gene Therapy Community Center: Listening Session on Thursday
Tracking the CIRM: Electing a New Chair, Other Job Openings, Grant Application Deadlines
A California Search: Forging a Path to Pay for Multimillion-Dollar Gene Therapies for Rare Diseases?
Tracking the CIRM: New Chair Election This Month, Latest Job Postings
California's Bubble Baby Saga: The Most-Read Tale of 2022
More Than a Seat at the Table: Overcoming the Ethical Obstacles in Stem Cell and Gene Therapy
Touchy Bioethical Issues and the California Stem Cell Agency: Revived CIRM Effort Begins This Week
IOM/NAM on California Stem Cell Agency Bioethical Standards
What is the CIRM Standards Group? Here's the Answer from State Law